80 Participants Needed

DR-01 for Alopecia Areata and Vitiligo

Recruiting at 24 trial locations
DC
Overseen ByDren Central Contact
Age: 18+
Sex: Any
Trial Phase: Phase 1
Sponsor: Dren Bio
Must be taking: Bimatoprost, Minoxidil
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This is a multi-center, parallel-group, open-label, randomized, Phase 1b study to explore the safety, clinical activity, pharmacokinetics and pharmacodynamics of DR-01 in adults with Alopecia Areata or Vitiligo.

Will I have to stop taking my current medications?

The trial requires that you do not start new medications or change dosages for any existing medications for reasons other than vitiligo. You must stay on a stable medication regimen during the study. Additionally, certain medications like JAK inhibitors, lymphocyte depleting agents, and oral immune suppressants must be stopped before the trial.

How is the drug DR-01 unique for treating alopecia areata and vitiligo?

DR-01 is a novel treatment because it is a human anti-CD94 IgG1 monoclonal antibody, which targets specific immune cells involved in the autoimmune response, potentially offering a new mechanism of action compared to existing treatments for alopecia areata and vitiligo.12345

What data supports the effectiveness of the drug DR-01 for treating alopecia areata and vitiligo?

There is no direct data on DR-01, but a study on a similar treatment using a monoclonal antibody to CD20 showed improvement in some vitiligo patients. This suggests that targeting immune cells with antibodies might help in treating these conditions.34567

Who Is on the Research Team?

MR

Michael Rothenberg, MD, PhD

Principal Investigator

Dren Bio

Are You a Good Fit for This Trial?

This trial is for adults with Alopecia Areata or Vitiligo. Specific eligibility criteria are not provided, but typically participants must meet certain health standards and may be excluded based on other medical conditions or treatments.

Inclusion Criteria

Agree to not use adhesive wigs during the study
Agree not to use any AA treatments during the study
Women of childbearing potential must agree to use a highly effective method of contraception
See 8 more

Exclusion Criteria

Intolerance or allergy to the investigational product or any of its components
Specific exclusion criteria for Alopecia Areata and Vitiligo
Known history of chronic alcohol abuse, IV drug abuse or illicit drug abuse within 1 year before screening
See 10 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive DR-01 at various dose levels for up to 6 months

6 months

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • DR-01
Trial Overview The study tests DR-01's safety, effectiveness, and how the body processes it in patients with Alopecia Areata or Vitiligo. It's an early-phase trial (Phase 1b), meaning it's one of the first times this drug is being tested in humans.
How Is the Trial Designed?
4Treatment groups
Experimental Treatment
Group I: DL4 of DR-01Experimental Treatment1 Intervention
Group II: DL3 of DR-01Experimental Treatment1 Intervention
Group III: DL2 of DR-01Experimental Treatment1 Intervention
Group IV: DL1 of DR-01Experimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Dren Bio

Lead Sponsor

Trials
6
Recruited
280+

Published Research Related to This Trial

In a study involving 9 patients with alopecia areata and alopecia universalis, as well as 6 patients with psoriasis, a higher proportion of T lymphocytes with Fc receptors for IgG (Tg cells) was found in those with alopecia and psoriasis compared to normal donors.
Despite the increased Tg cells, the overall proportions of total T lymphocytes and other specific T cell subpopulations were within normal ranges, suggesting a complex immune response in these conditions that may involve different T cell subpopulations.
T lymphocyte subpopulations in alopecia areata and psoriasis: identification with monoclonal antibodies and Fc receptors.Gu, SQ., Petrini, B., Ros, AM., et al.[2006]
In patients with alopecia areata (AA), specific synthetic epitopes from hair follicle antigens trichohyalin and tyrosinase-related protein-2 triggered a stronger immune response in cytotoxic T cells compared to healthy individuals, indicating a potential mechanism for the autoimmune nature of the disease.
The study found that activated T cells from AA patients released factors that increased apoptosis in hair follicle keratinocytes, suggesting that the immune response to these self-antigens could serve as a prognostic marker for the disease.
Identification of Autoantigen Epitopes in Alopecia Areata.Wang, EHC., Yu, M., Breitkopf, T., et al.[2022]
In a small study of five patients with active disseminated vitiligo, a single intravenous infusion of a chimeric monoclonal antibody to CD20 resulted in significant clinical and histological improvement in three patients, indicating potential efficacy of this treatment.
The observed improvements were not linked to changes in laboratory parameters or specific HLA-DR phenotypes, suggesting that further research is needed to identify reliable markers for response to this therapy.
Treatment of vitiligo with a chimeric monoclonal antibody to CD20: a pilot study.Ruiz-Argรผelles, A., Garcรญa-Carrasco, M., Jimenez-Brito, G., et al.[2023]

Citations

T lymphocyte subpopulations in alopecia areata and psoriasis: identification with monoclonal antibodies and Fc receptors. [2006]
Identification of Autoantigen Epitopes in Alopecia Areata. [2022]
Treatment of vitiligo with a chimeric monoclonal antibody to CD20: a pilot study. [2023]
Western blot analysis of serum antibody reactivity with human melanoma cell antigens in alopecia areata and vitiligo. [2019]
Detection of antibodies to human melanoma cells in vitiligo and alopecia areata by Western blot analysis. [2006]
Evaluation of the Relationship between Alopecia Areata and Viral Antigen Exposure. [2018]
Alopecia areata universalis elicited during treatment with adalimumab. [2015]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of ServiceยทPrivacy PolicyยทCookiesยทSecurity